Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEKTAR THERAPEUTICS

(NKTR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nektar Therapeutics Shares Rise 5% on Deal With Pfizer, Merck KGaA

09/21/2021 | 01:30pm EDT

By Chris Wack

Nektar Therapeutics shares were up 5% to $17.10 after the company said it entered into a new oncology clinical collaboration with Merck KGaA and Pfizer Inc.

The deal is for the company to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in a Phase II study.

NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid tumors. The novel IL-15 agonist is designed to activate the IL-15 pathway to expand both natural killer cells and memory CD8+ T cell populations.

Avelumab, which is marketed in the U.S. as Bavencio, is co-developed and co-commercialized by Merck KGaA and Pfizer Inc.

Under the new collaboration, Merck KGaA and Pfizer Inc. will include the combination of NKTR-255 plus avelumab in the study. Nektar will supply NKTR-255 for the trial. Nektar and the Merck KGaA-Pfizer alliance will each maintain existing global commercial rights to their respective medicines. The study is expected to begin enrolling patients in the first quarter of 2022.

Nektar stock hit its 52-week low of $12.92 on Aug. 20.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

09-21-21 1329ET

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA 2.26% 199.6 Delayed Quote.38.97%
NEKTAR THERAPEUTICS -1.50% 16.32 Delayed Quote.-2.00%
PFIZER, INC. 0.90% 42.545 Delayed Quote.12.25%
All news about NEKTAR THERAPEUTICS
09/23Redhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation w..
MT
09/22NEKTAR THERAPEUTICS : Thinking about trading options or stock in Ambarella, Robinhood Mark..
PR
09/21Nektar Therapeutics Shares Rise 5% on Deal With Pfizer, Merck KGaA
DJ
09/21NEKTAR THERAPEUTICS : Partners With Pfizer, Merck for Clinical Trial
MT
09/21NEKTAR THERAPEUTICS : Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germ..
PR
09/21Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfiz..
CI
09/17NEKTAR THERAPEUTICS : Corporate Presentation September 2021
PU
08/18INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Nektar Therapeutics
MT
08/18INSIDER TRENDS : Nektar Therapeutics Insider Extends 90-Day Selling Trend
MT
08/18INSIDER TRENDS : Selling By Insiders Lingers at Nektar Therapeutics
MT
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
More recommendations
Financials (USD)
Sales 2021 109 M - -
Net income 2021 -552 M - -
Net cash 2021 484 M - -
P/E ratio 2021 -5,52x
Yield 2021 -
Capitalization 3 062 M 3 062 M -
EV / Sales 2021 23,6x
EV / Sales 2022 7,08x
Nbr of Employees 718
Free-Float 99,1%
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | MarketScreener
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 16,66 $
Average target price 29,50 $
Spread / Average Target 77,1%
EPS Revisions
Managers and Directors
Howard W. Robin President, Chief Executive Officer & Director
Gilbert M. Labrucherie Chief Operating & Financial Officer
Robert B. Chess Chairman
Jonathan Zalevsky Chief Research & Development Officer
Dimitry S. A. Nuyten Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-2.00%3 062
MODERNA, INC.219.34%134 660
LONZA GROUP AG27.07%58 240
IQVIA HOLDINGS INC.38.99%47 715
SEAGEN INC.-0.54%31 691
CELLTRION, INC.-39.28%25 332